

**EISNERAMPER**

**THE FIBROLAMELLAR CANCER  
FOUNDATION**

**FINANCIAL STATEMENTS**

**DECEMBER 31, 2021**



# THE FIBROLAMELLAR CANCER FOUNDATION

## Contents

	<b><u>Page</u></b>
<b>Independent Auditors' Report</b>	1
<b>Financial Statements</b>	
Statement of Financial Position as of December 31, 2021	3
Statement of Activities for the year ended December 31, 2021	4
Statement of Functional Expenses for the year ended December 31, 2021	5
Statement of Cash Flows for the year ended December 31, 2021	6
Notes to financial statements	7

## INDEPENDENT AUDITORS' REPORT

To the Board of Directors of  
The Fibrolamellar Cancer Foundation

### Report on the Financial Statements

#### *Opinion*

We have audited the financial statements of The Fibrolamellar Cancer Foundation (the "Foundation"), which comprise the statement of financial position as of December 31, 2021, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of The Fibrolamellar Cancer Foundation as of December 31, 2021, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

#### *Basis for Opinion*

We conducted our audit in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Foundation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### *Responsibilities of Management for the Financial Statements*

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.



"EisnerAmper" is the brand name under which EisnerAmper LLP and Eisner Advisory Group LLC provide professional services. EisnerAmper LLP and Eisner Advisory Group LLC are independently owned firms that practice in an alternative practice structure in accordance with the AICPA Code of Professional Conduct and applicable law, regulations and professional standards. EisnerAmper LLP is a licensed CPA firm that provides attest services, and Eisner Advisory Group LLC and its subsidiary entities provide tax and business consulting services. Eisner Advisory Group LLC and its subsidiary entities are not licensed CPA firms.

## ***Auditors' Responsibilities for the Audit of the Financial Statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

*EisnerAmper LLP*

EISNERAMPER LLP  
Iselin, New Jersey  
November 15, 2022



# THE FIBROLAMELLAR CANCER FOUNDATION

## Statement of Financial Position December 31, 2021

### ASSETS

Cash and cash equivalents	\$ 3,665,906
Investments	3,886,573
Contributions receivable	94,000
Prepaid expenses	16,557
Equipment, net	<u>1,436</u>
Total assets	<u><u>\$ 7,664,472</u></u>

### LIABILITIES

Accounts payable and accrued expenses	\$ 213,162
Due to related party	54,838
Grants payable	<u>1,335,313</u>
Total liabilities	<u><u>1,603,313</u></u>

Contingency and other uncertainty (see Note J)

### NET ASSETS

Without donor restrictions	5,818,912
With donor restrictions	<u>242,247</u>
Total net assets	<u><u>6,061,159</u></u>
Total liabilities and net assets	<u><u>\$ 7,664,472</u></u>

# THE FIBROLAMELLAR CANCER FOUNDATION

## Statement of Activities Year Ended December 31, 2021

	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>	<u>Total</u>
<b>Revenues:</b>			
Contributions	\$ 4,039,921	\$ -	\$ 4,039,921
Special event	188,170	-	188,170
Less: direct benefit to donors	(188,170)	-	(188,170)
Investment income, net	344,524	-	344,524
In-kind contributions	56,550	-	56,550
Net assets released from restrictions	165,815	(165,815)	-
	<u>4,606,810</u>	<u>(165,815)</u>	<u>4,440,995</u>
Total revenues			
<b>Expenses:</b>			
Grants for research	957,000	-	957,000
Compensation	534,382	-	534,382
Outside services	139,837	-	139,837
Program - venue cost	21,586	-	21,586
Program - travel cost	17,922	-	17,922
Research	70,655	-	70,655
Accounting and administrative services	56,550	-	56,550
Information technology	59,036	-	59,036
Miscellaneous	77,914	-	77,914
	<u>1,934,882</u>	<u>-</u>	<u>1,934,882</u>
Total expenses			
<b>Change in net assets</b>	<b>2,671,928</b>	<b>(165,815)</b>	<b>2,506,113</b>
Net assets, beginning of year	<u>3,146,984</u>	<u>408,062</u>	<u>3,555,046</u>
<b>Net assets, end of year</b>	<u><u>\$ 5,818,912</u></u>	<u><u>\$ 242,247</u></u>	<u><u>\$ 6,061,159</u></u>

# THE FIBROLAMELLAR CANCER FOUNDATION

## Statement of Functional Expenses Year Ended December 31, 2021

	Program Services	Supporting Services		Total
	Awareness and Research	Management and General	Fundraising	
Grants for research	\$ 957,000	\$ -	\$ -	\$ 957,000
Compensation	202,387	331,995	-	534,382
Special event - meals and golf fees	-	-	188,170	188,170
Outside services	113,782	26,055	-	139,837
Program - venue cost	21,586	-	-	21,586
Program - travel cost	17,922	-	-	17,922
Research	70,655	-	-	70,655
Accounting and administrative services	-	56,550	-	56,550
Information technology	33,200	25,836	-	59,036
Miscellaneous	14,153	46,400	17,361	77,914
	<u>1,430,685</u>	<u>486,836</u>	<u>205,531</u>	<u>2,123,052</u>
Total expenses by function	1,430,685	486,836	205,531	2,123,052
Less: expenses included in the revenue section on the statement of activities:				
Cost of direct benefit to donors	-	-	(188,170)	(188,170)
	<u>-</u>	<u>-</u>	<u>(188,170)</u>	<u>(188,170)</u>
Total expenses included in the expense section on the statement of activities	<u>\$ 1,430,685</u>	<u>\$ 486,836</u>	<u>\$ 17,361</u>	<u>\$ 1,934,882</u>

# THE FIBROLAMELLAR CANCER FOUNDATION

## Statement of Cash Flows Year Ended December 31, 2021

### Cash flows from operating activities:

Change in net assets	\$ 2,506,113
Adjustments to reconcile change in net assets to net cash provided by operating activities:	
Depreciation expense	784
Unrealized gain on investments	(330,056)
Donated securities	(932,987)
Proceeds from sale of donated securities	932,987
Changes in:	
Contribution receivable	(93,905)
Prepaid expenses	(16,557)
Accounts payable and accrued expenses	129,117
Due to related party	45,913
Grants payable	<u>(412,353)</u>
Net cash provided by operating activities	<u>1,829,056</u>
<b>Net change in cash and cash equivalents</b>	<b>1,829,056</b>
Cash and cash equivalents, beginning of year	<u>1,836,850</u>
<b>Cash and cash equivalents, end of year</b>	<b><u>\$ 3,665,906</u></b>



# THE FIBROLAMELLAR CANCER FOUNDATION

## Notes to Financial Statements December 31, 2021

### NOTE A - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### [1] Organization:

The Fibrolamellar Cancer Foundation (the "Foundation") is a not-for-profit organization organized under the laws of the State of Delaware. The Foundation was established to raise awareness and research funds for fibrolamellar hepatocellular carcinoma, a rare form of liver cancer that is primarily seen in teens and young adults. Currently, there are no viable treatment options other than liver resection surgery. The Foundation's mission is to find a cure and reliable treatment options for those diagnosed with this rare disease, as well as enhance communication among healthcare professionals and patients.

The Foundation devotes all its time to fundraising, grant-making and building collaborative relationships to support these causes. The activities of the Foundation began in June 2009 and are conducted by the Board of Directors and officers of the Foundation.

#### [2] Basis of presentation:

These financial statements, which are presented on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), have been prepared to focus on the Foundation as a whole and to present balances and transactions according to the existence or absence of donor-imposed restrictions. Accordingly, net assets and changes therein are classified as follows:

- Net assets without donor restrictions - net assets available for use in general operations and not subject to donor-imposed stipulations.
- Net assets with donor restrictions - net assets subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates those resources be maintained in perpetuity by the Foundation. Donor-imposed restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both. Donor restricted contributions whose restrictions are met in the same reporting period are reported as revenue without donor restrictions.

Revenue is reported as increases in net assets without donor restrictions unless use of the related asset is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains on investments and other assets or liabilities are reported as increases or decreases in net assets without donor restrictions unless their use is restricted by donor stipulation or by law. Expirations of time or purpose restrictions on net assets are reported as net assets released from restrictions.

#### [3] Use of estimates:

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.

# THE FIBROLAMELLAR CANCER FOUNDATION

## Notes to Financial Statements December 31, 2021

### NOTE A - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

#### [4] Cash and cash equivalents:

Cash and cash equivalents include highly liquid investments with initial maturity dates of three months or less.

#### [5] Investments:

The Foundation accounts for its investments in accordance with relevant authoritative guidance, which defines fair value, establishes a framework for measuring fair value, and requires enhanced disclosures about fair value measurements. Investments are reflected on the statement of financial position at fair value, with changes in unrealized gains and losses resulting from changes in fair value reflected in investment income reported in the statement of activities. Fair value is the estimated amount that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.

Investments consist of investments in limited partnerships that are non-marketable. The net asset value provided by the partnerships' management is used as a practical expedient measurement of fair value. This method may produce a fair value estimate that may not be indicative of the net realizable value or reflective of future values. Furthermore, although management believes this valuation method is appropriate and consistent with the practices of other market participants, the use of different methodologies or assumptions to determine fair value could result in a different fair value measurement at the reporting date.

Investments received as contributions, if any, are initially recorded at fair value at the date of receipt. Realized gains and losses and the change in unrealized gains and losses resulting from changes in fair value are reflected in the investment income reported in the statement of activities.

Users of these financial statements should be aware that the financial markets' volatility may significantly impact the subsequent valuation of the Foundation's investments. Accordingly, the valuation of investments may not necessarily be indicative of amounts that could be realized in a current market exchange.

#### [6] Equipment:

Equipment is stated at cost less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful life of the equipment of 5 years. The Foundation capitalizes all equipment with a cost of \$1,000 or greater and expenses all repairs and maintenance as incurred.

#### [7] Revenue recognition:

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, *Revenue from Contracts with Customers*, and has subsequently issued supplemental and/or clarifying ASUs (collectively, Accounting Standards Codification ("ASC") 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 outlines a five-step framework that supersedes the principles for recognizing revenue and eliminates industry specific guidance. In addition, ASC 606 revises current disclosure requirements in an effort to help financial statement users better understand the nature, amount, timing and uncertainty of revenue that is recognized. The Foundation adopted ASC 606, using the modified retrospective approach. There was no effect on net assets in connection with the implementation of this ASU.

# THE FIBROLAMELLAR CANCER FOUNDATION

## Notes to Financial Statements December 31, 2021

### NOTE A - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

#### [7] Revenue recognition: (continued)

The Foundation receives support in the form of contributions from corporations, foundations and individuals. Contributions, including unconditional promises to give, are recognized as revenue in the period received. Contributions of assets other than cash are recorded at fair value at the date of donation. Contributions to be received after one year are discounted at a rate commensurate with the risk involved. Conditional promises to give, that is, those with a measurable performance or other barrier and a right of return, are not recognized until the conditions on which they depend have been met.

The Foundation records special events revenue equal to the cost of direct benefits to donors, and contribution revenue (difference between the cash receipt and the direct benefit), which is included in special events in the statement of activities. The recognition of revenue is conditional on the event taking place, as this is the point in time when the performance obligation of hosting the event occurs, and attendees can no longer request a refund for their tickets purchased.

As of December 31, 2021, the Foundation's golf outing generated revenue of \$1,209,460, of which \$188,170, was reported as special event revenue and the remaining amount was reported in contribution revenue. Related expenses of the golf outing totaled \$188,170. As of December 31, 2021, contribution receivable of \$94,000 was reported in the statement of activities for amounts due from the special event, and no amounts were reserved for.

#### [8] Income taxes:

The Internal Revenue Service ("IRS") has determined that the Foundation qualifies as a tax-exempt organization under Section 501(c)(3) of the Internal Revenue Code ("IRC") and is exempt from tax on related income pursuant to Section 501(a) of the IRC. The Foundation is classified as a public charity. Accordingly, no provision for income taxes has been recorded in the accompanying financial statements.

Management has analyzed the tax positions taken by the Foundation, and has concluded that as of December 31, 2021, there are no uncertain positions taken or expected to be taken that would require the recognition of a liability or disclosure in these financial statements. The Foundation recognizes accrued interest and penalties associated with uncertain tax provisions, if any. There were no income tax-related interest and penalties recorded for the year ended December 31, 2021.

#### [9] Donated services:

Donated services are recognized as revenues and expenses if the services received (a) create or enhance nonfinancial assets, or (b) require specialized skills that are provided by individuals possessing those skills and would typically need to be purchased if not provided by donation.

#### [10] Functionalized expenses:

The financial statements report certain categories of expenses that are attributed to more than one program or supporting function. Therefore, expenses require allocation on a reasonable basis that is consistently applied. Compensation, outside services and miscellaneous expenses are based on actual time or cost associated with the account.

# THE FIBROLAMELLAR CANCER FOUNDATION

## Notes to Financial Statements December 31, 2021

### NOTE A - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

#### [11] Upcoming accounting pronouncement:

In September 2020, the FASB issued ASU No. 2020-07, *Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets* (Topic 958). The objective of ASU 2020-07, along with its subsequent amendment, is to increase transparency of contributed nonfinancial assets for not-for-profit entities through enhancements in presentation and disclosure requirements. Not-for-profit entities will now be required to present contributed nonfinancial assets as a separate line item in the statement of activities, apart from contributions of cash and other financial contributions. Not-for-profit entities will also be required to disclose various information related to contributed nonfinancial assets. The amendment in this update should be applied on a retrospective basis and is effective for annual periods beginning after June 15, 2021, and interim periods within annual periods beginning after June 15, 2022. The Foundation is currently evaluating the effect that the new standard will have on its financial statements and related disclosures.

#### [12] Subsequent events:

The Foundation evaluated events through November 15, 2022, which was the date the financial statements were available to be issued.

### NOTE B - EQUIPMENT

Equipment at December 31, 2021 consists of the following:

Equipment	\$ 3,917
Less: accumulated depreciation	<u>(2,481)</u>
Total	<u>\$ 1,436</u>

Depreciation expense for the year ended December 31, 2021 was \$784.

### NOTE C - INVESTMENTS

The Foundation invested \$3,000,000 in limited partnership hedge funds that were valued at \$3,886,573 as of December 31, 2021.

Net investment income is reported in the statement of activities and consists of net unrealized gains on investments of \$330,056, and interest and other investment income of \$14,468.

### NOTE D - FAIR VALUE MEASUREMENTS

Limited partnership interests measured at net asset value ("NAV") totaled \$3,886,573. The Foundation's investments are measured at fair value using the NAV per share (or its equivalent) as a practical expedient and therefore are not classified in the fair value hierarchy.

# THE FIBROLAMELLAR CANCER FOUNDATION

## Notes to Financial Statements December 31, 2021

### NOTE D - FAIR VALUE MEASUREMENTS (CONTINUED)

Information regarding the nature and risk of certain investments reported at NAV as of December 31, 2021 is as follows:

<u>Investment</u>	<u>Fair Value</u>	<u>Unfunded Commitments</u>	<u>Redemption Frequency</u>	<u>Redemption Notice Period</u>
Limited Partnerships:				
Floating Rate Funds (a)	\$ 2,600,389	\$ -	Monthly	45 Days
Credit Opportunities Fund (b)	1,286,184	-	Quarterly	60 Days

- (a) Floating Rate Funds invest primarily in senior secured and second lien bank loans and bonds.  
(b) Credit Opportunities Fund invests primarily in corporate credit-related assets.

### NOTE E - TRANSACTION WITH RELATED PARTIES

Certain directors and officers of the Foundation are officers and employees of Stone Point Capital LLC ("SPC"). Additionally, SPC provides several services at no cost to the Foundation, which include accounting and communications. The estimated value of these services amounted to \$56,550, which was recorded as both an in-kind contribution and accounting and administrative services expense in the statement of activities. In 2021, donations from the Charles A. and Marna Davis Foundation of \$370,000 and from SPC covered all administrative costs of the Foundation, so that 100% of donations received from others are available to fund program services. As of December 31, 2021, the Foundation had a liability to SPC of \$54,838.

### NOTE F - GRANTS PAYABLE

Grants payable are recognized in the accompanying financial statements at the time of Foundation approval. The Foundation's grants payable at December 31, 2021 are payable as follows:

Less than one year	\$ 1,151,232
One to five years	<u>184,081</u>
Total grants payable	<u>\$ 1,335,313</u>

The amount of the discount to net present value of the grants payable in more than one year was immaterial to these financial statements. For the year ended December 31, 2021, the Foundation approved \$957,000 of new grants, and paid grants of \$1,369,353.

Conditional grants and promises to give are not recorded as expenses until the condition on which they depend have been met. A grant is deemed to be conditional if it includes one or more measurable barriers and a right of return or forfeiture. As of December 31, 2021, grants conditioned on meeting proof of concept stipulated in the grant agreement totaled \$685,000.

# THE FIBROLAMELLAR CANCER FOUNDATION

## Notes to Financial Statements December 31, 2021

### NOTE G - NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions are restricted for the following purposes for the year ended December 31, 2021 as follows:

	<u>2021</u>
Purpose restrictions:	
CZI Grant Research	<u>\$ 242,247</u>

Net assets were released from donor restrictions by incurring expenses satisfying the restricted purpose or by occurrence of the passage of time or other events specified by the donors as follows for the year ended December 31, 2021:

	<u>2021</u>
Satisfaction of purpose restriction:	
CZI Grant Research	<u>\$ 165,815</u>

### NOTE H - PROGRAM COSTS

The Foundation sponsors events to help facilitate communication within the fibrolamellar community. Such events include a Patients' Gathering and Doctors' Summit. Travel expenses incurred for these events totaled \$17,922 and venue costs related to the Doctors' Summit totaled \$21,586 in 2021.

### NOTE I - LIQUIDITY AND AVAILABILITY OF RESOURCES

The Foundation's financial assets available for general expenditure within one year of the statement of financial position date are as follows:

Cash and cash equivalents	\$ 3,665,906
Investments	3,886,573
Contributions receivable	<u>94,000</u>
	7,649,479
Less amounts unavailable for general expenditure within one year:	
Net assets with donor restrictions – purpose restriction	<u>(242,247)</u>
Total financial assets available to meet cash needs for general expenditure within one year	<u>\$ 7,404,232</u>

The Foundation maintains a policy of structuring its financial assets to be available as its general expenditures, liabilities and other obligations come due. In addition, the Foundation invests cash in excess of short-term requirements.

# **THE FIBROLAMELLAR CANCER FOUNDATION**

## **Notes to Financial Statements December 31, 2021**

### **NOTE J - RISK AND UNCERTAINTY**

The coronavirus (“COVID-19”) pandemic continues to be a major global health crisis. The extent of the impact and effects of the pandemic of COVID-19 on the operation and financial performance of the Foundation’s business is unknown. However, the Foundation does not expect that the pandemic will have a material adverse effect on the business or financial results at that this time.